MedTrace Logo

The Efficacy and Safety of Daptomycin in the Treatment of Gram-positive Bacterial Infection.

NCT04546815 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2020-09-17

No results posted yet for this study

Summary

This study aims to collect and analyze clinical data of daptomycin to explore the efficacy and safety of daptomycin in the treatment of Gram-positive bacterial infections. And optimize the dosing regimen based on these data.

Conditions

  • Antibiotic

Interventions

DRUG

Daptomycin

According to the severity of the disease, the site of infection and clinical response, the doctor makes a drug regimen of datoramycin.

Sponsors & Collaborators

  • Jiangsu Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • XiaoJun X Ma, doctor · Peking Union Medical College Hospital

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-25
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04546815 on ClinicalTrials.gov